santa barbara
emerg growth medic aesthet
clinic differenti breast implant portfolio
board certifi plastic
surgeon complement
anti-scar
treatment fda clear silishield soon
hair treatment
reason report
estim chang analysi sales/earn
reiter o/v invest rate price target
share compani growth outlook remain effect
on-track see potenti increment top-lin growth post
upcom fda panel inform consum
return marketplac also increasingli opt opu
implant base devic favor clinic profil street
consensu breast busi expect reduc reflect
conserv fh outlook increas oper spend
miradri opu combin increas oper loss
remain opinion investor accumul share
histor trough multipl med tech order benefit
expect acceler growth
maintain price maintain price
target per share recal per share price
target base revenu multipl
fine-tun estim fine-tun former revenu
loss estim reflect modestli softer fh outlook
augment marketplac increas expens support
miradri opu modest reduct ramp
miradri consum sale specif lower former
million revenu estim increas
former loss estim per share likewis
moder former million revenu estim
increas per share loss estim
guidanc review continu prudent postpon
establish formal corpor guidanc upcom
fda panel compani establish expect relat devic
sale increas minimum versu million
impli minimum sale million versu pre-cal consensu
million addit compani reiter confid
miradri continu drive acceler revenu growth opinion
effect reign street expect light uncertainti
surround upcom panel prudent like weight
share immedi short-run
valuat summari share current valu ev/
revenu versu compar med tech industri peer trade
averag revenu multipl
import disclosur analyst certif page report access current disclosur stephen
inc cover compani client may refer
bottom line despit prevail uncertainti weigh domest breast augment market
step establish expect relat devic sale increas minimum versu
domest end market estim grow impress approxim million impli
reduct pre-cal consensu breast product revenu like weight share immedi
near-term addit formal guidanc provid miradri revenu growth compani
indic relat devic sale grow acceler pace accordingli moder breast implant revenu
estim million miradri estim million biocorneum estim million estim
realiz annual revenu growth prior corpor revenu growth acceler year-over-
year addit recur theme across med tech compani plan increas
sale market expenditur drive continu adopt miradri addit market share gain
opu accordingli increas former million oper expens assumpt million
million reduct former expens estim off-set million increas sale
market expens assumpt million increas estim reflect plan step-up
relat expenditur increas oper expenditur account proverbi lion share
increas annual loss estim share like open valuat essenti in-lin
trough multipl small cap med tech growth compani favor organ growth outlook like near-
term catalyst sustain acceler growth post fda panel favor dispos rel risk
reward set-up share
oper summari report record quarterli revenu million pre-cal consensu million
repres annual increas compani quarterli revenu driven breast product sale
increas million compani miradri busi increas million quarterli
gross margin increas year-ov year oper expens increas year-over-year
million result report loss per share pre-cal consensu
intern expans reiter compani commit late expans canadian
market follow compani prior medic devic applic health canada oper period
outsid north america compani plan identifi top market abl perform
control launch becom one three fda approv silicon breast implant market commerci
fda panel industri news present headwind expect upcom fda panel associ
media coverag ahead march panel date result reduct number consult
also procedur across domest marketplac moreov prevail malais expect continu hinder
macro market growth throughout fh recal previous lower breast implant revenu assumpt
follow revoc ce mark textur implant brought neg attent industri
addit mention panel headwind follow call yesterday reduc breast implant
revenu estim million million million reflect revis assumpt domest
procedur trend flat year-over-year prior re-acceler throughout
miradri provid street bogey growth compani breast implant busi
compani provid formal guidanc miradri busi recal earli februari compani announc
appoint kirk gunhu gener manag miradri busi replac patrick william longer
follow announc lower revenu estim million million impli
year-over-year growth lieu guidanc base review capit consum sale growth
assumpt reduc miradri revenu growth estim million owe conservat
million impli annual growth
balanc sheet exit oper period million cash cash equival total debt
million net cash posit million net cash per share compani indic quarterli
cash burn expect remain averag million rate inclus miradri mileston payment
consolid statement oper
million except per share data
fiscal period
fiscal period
fiscal period
good sold
sale market
research develop
gener administr
incom loss oper
compani file stephen estim
analyst primarili respons prepar content report certifi view express report
accur reflect analyst person view subject compani secur ii part analyst compens
directli indirectli relat specif recommend view express analyst report
